Logo image of PSNL

PERSONALIS INC (PSNL) Stock Fundamental Analysis

NASDAQ:PSNL - Nasdaq - US71535D1063 - Common Stock - Currency: USD

3.68  +0.27 (+7.92%)

After market: 3.68 0 (0%)

Fundamental Rating

3

Overall PSNL gets a fundamental rating of 3 out of 10. We evaluated PSNL against 55 industry peers in the Life Sciences Tools & Services industry. The financial health of PSNL is average, but there are quite some concerns on its profitability. PSNL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PSNL had negative earnings in the past year.
PSNL had a negative operating cash flow in the past year.
In the past 5 years PSNL always reported negative net income.
In the past 5 years PSNL always reported negative operating cash flow.
PSNL Yearly Net Income VS EBIT VS OCF VS FCFPSNL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

PSNL has a worse Return On Assets (-30.08%) than 76.36% of its industry peers.
With a Return On Equity value of -40.05%, PSNL is not doing good in the industry: 65.45% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -30.08%
ROE -40.05%
ROIC N/A
ROA(3y)-38.97%
ROA(5y)-30.04%
ROE(3y)-58.56%
ROE(5y)-43.57%
ROIC(3y)N/A
ROIC(5y)N/A
PSNL Yearly ROA, ROE, ROICPSNL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

PSNL's Gross Margin of 31.70% is on the low side compared to the rest of the industry. PSNL is outperformed by 70.91% of its industry peers.
In the last couple of years the Gross Margin of PSNL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for PSNL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.05%
GM growth 5Y-1.31%
PSNL Yearly Profit, Operating, Gross MarginsPSNL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

More info and screens

5

2. Health

2.1 Basic Checks

PSNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSNL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PSNL has more shares outstanding
The debt/assets ratio for PSNL has been reduced compared to a year ago.
PSNL Yearly Shares OutstandingPSNL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PSNL Yearly Total Debt VS Total AssetsPSNL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PSNL has an Altman-Z score of 0.08. This is a bad value and indicates that PSNL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PSNL (0.08) is worse than 70.91% of its industry peers.
PSNL has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PSNL has a Debt to Equity ratio of 0.00. This is in the better half of the industry: PSNL outperforms 76.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACC10.56%
PSNL Yearly LT Debt VS Equity VS FCFPSNL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.52 indicates that PSNL has no problem at all paying its short term obligations.
PSNL's Current ratio of 6.52 is amongst the best of the industry. PSNL outperforms 83.64% of its industry peers.
A Quick Ratio of 6.33 indicates that PSNL has no problem at all paying its short term obligations.
The Quick ratio of PSNL (6.33) is better than 83.64% of its industry peers.
Industry RankSector Rank
Current Ratio 6.52
Quick Ratio 6.33
PSNL Yearly Current Assets VS Current LiabilitesPSNL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.68% over the past year.
The Revenue has grown by 15.14% in the past year. This is quite good.
PSNL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.35% yearly.
EPS 1Y (TTM)35.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.41%
Revenue 1Y (TTM)15.14%
Revenue growth 3Y-0.34%
Revenue growth 5Y5.35%
Sales Q2Q%-14.61%

3.2 Future

Based on estimates for the next years, PSNL will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.56% on average per year.
Based on estimates for the next years, PSNL will show a very strong growth in Revenue. The Revenue will grow by 30.03% on average per year.
EPS Next Y24.06%
EPS Next 2Y15.78%
EPS Next 3Y13.42%
EPS Next 5Y17.56%
Revenue Next Year-1.04%
Revenue Next 2Y12.45%
Revenue Next 3Y17.79%
Revenue Next 5Y30.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PSNL Yearly Revenue VS EstimatesPSNL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
PSNL Yearly EPS VS EstimatesPSNL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PSNL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PSNL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSNL Price Earnings VS Forward Price EarningsPSNL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSNL Per share dataPSNL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as PSNL's earnings are expected to grow with 13.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.78%
EPS Next 3Y13.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PSNL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PERSONALIS INC

NASDAQ:PSNL (4/23/2025, 8:00:01 PM)

After market: 3.68 0 (0%)

3.68

+0.27 (+7.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)04-30 2025-04-30/amc
Inst Owners67.44%
Inst Owner Change-0.02%
Ins Owners1.06%
Ins Owner Change-0.32%
Market Cap324.98M
Analysts81.54
Price Target7.48 (103.26%)
Short Float %6.54%
Short Ratio3.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.2%
Min EPS beat(2)-79.27%
Max EPS beat(2)20.88%
EPS beat(4)3
Avg EPS beat(4)3.98%
Min EPS beat(4)-79.27%
Max EPS beat(4)37.32%
EPS beat(8)5
Avg EPS beat(8)3.21%
EPS beat(12)7
Avg EPS beat(12)2.92%
EPS beat(16)11
Avg EPS beat(16)5.51%
Revenue beat(2)2
Avg Revenue beat(2)11.43%
Min Revenue beat(2)4.66%
Max Revenue beat(2)18.2%
Revenue beat(4)4
Avg Revenue beat(4)10.51%
Min Revenue beat(4)4.27%
Max Revenue beat(4)18.2%
Revenue beat(8)6
Avg Revenue beat(8)6.37%
Revenue beat(12)10
Avg Revenue beat(12)6.95%
Revenue beat(16)12
Avg Revenue beat(16)5.04%
PT rev (1m)-0.9%
PT rev (3m)-4.14%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)19.24%
EPS NY rev (1m)5.41%
EPS NY rev (3m)6.28%
Revenue NQ rev (1m)-0.48%
Revenue NQ rev (3m)-0.48%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)-5.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.84
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.96
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.08%
ROE -40.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.7%
FCFM N/A
ROA(3y)-38.97%
ROA(5y)-30.04%
ROE(3y)-58.56%
ROE(5y)-43.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.05%
GM growth 5Y-1.31%
F-Score5
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.65%
Cap/Sales 1.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.52
Quick Ratio 6.33
Altman-Z 0.08
F-Score5
WACC10.56%
ROIC/WACCN/A
Cap/Depr(3y)234.39%
Cap/Depr(5y)188.79%
Cap/Sales(3y)31.15%
Cap/Sales(5y)22.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.41%
EPS Next Y24.06%
EPS Next 2Y15.78%
EPS Next 3Y13.42%
EPS Next 5Y17.56%
Revenue 1Y (TTM)15.14%
Revenue growth 3Y-0.34%
Revenue growth 5Y5.35%
Sales Q2Q%-14.61%
Revenue Next Year-1.04%
Revenue Next 2Y12.45%
Revenue Next 3Y17.79%
Revenue Next 5Y30.03%
EBIT growth 1Y29.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.76%
EBIT Next 3Y-0.31%
EBIT Next 5YN/A
FCF growth 1Y30.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.74%
OCF growth 3YN/A
OCF growth 5YN/A